Business UpdateMay 19, 2026, 04:32 PM
Cadrenal Therapeutics to Present at Lytham Partners Spring 2026 Investor Conference
AI Summary
Cadrenal Therapeutics, Inc. announced its participation in the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026. The company will host a webcast presentation at 9:30 a.m. ET and conduct virtual one-on-one meetings with investors. Cadrenal Therapeutics is a late-stage biopharmaceutical company developing therapies for immune and thrombotic conditions, with its lead program CAD-1005 for heparin-induced thrombocytopenia holding Orphan Drug and Fast Track designations.
Key Highlights
- Cadrenal Therapeutics will participate in the Lytham Partners Spring 2026 Investor Conference.
- A webcast presentation is scheduled for Thursday, May 28, 2026, at 9:30 a.m. ET.
- Management will host virtual one-on-one meetings with investors during the event.
- Cadrenal Therapeutics is a late-stage biopharmaceutical company advancing novel therapies.
- Its lead program, CAD-1005, targets heparin-induced thrombocytopenia (HIT).
- CAD-1005 has received Orphan Drug and Fast Track designations from the USFDA.
- The company's pipeline also includes tecarfarin and frunexian for various conditions.
Price Impact
More from CVKD